Personalised Cancer Immunotherapy

The KarMMa-3 study: CAR T cell therapy as personalised cancer immunotherapy for treatment-resistant multiple myeloma

The KarMMa-3 study: CAR T cell therapy as personalised cancer immunotherapy for treatment-resistant multiple myeloma